Hospital-at-home cuts cost and readmissions in trials. Mortality is roughly a wash

"Hospital-at-home" — delivering acute, hospital-level treatment in a patient's house with nurse and physician visits, intravenous drugs, remote monitoring and point-of-care testing — reduces cost and some measures of health-care use, and in the best trials it lowers readmissions, without evidence that patients are any more likely to die than in a ward. That last point is the one to hold onto: the case for hospital-at-home rests on equivalent safety at lower cost, not on better survival [s1][s2].

The randomised US trial

The clearest single piece of evidence is a randomised controlled trial run at a US academic medical centre and a community hospital, published in Annals of Internal Medicine [s1]. It enrolled 91 adults who arrived through the emergency department with selected acute conditions and randomly assigned 43 to acute care at home and 48 to usual hospital admission [s1].

The results favoured home care across the board on resource use. The adjusted mean cost of the episode was 38% lower for home patients (95% CI, 24% to 49%) [s1]. Home patients had far fewer laboratory orders (a median of 3 per admission versus 15), fewer imaging studies (14% versus 44%) and fewer specialist consultations (2% versus 31%) [s1]. They were also more physically active — spending less of the day lying down — and were readmitted less often within 30 days: 7% versus 23% [s1]. The authors were candid about the limits: two sites, a small number of home-visiting physicians, and 91 patients is not a large trial [s1].

The pooled picture

The broader evidence, from a 2024 Cochrane review of 20 randomised trials with 3,100 participants comparing admission-avoidance hospital-at-home with inpatient care, is more measured — and more useful, because it separates what changes from what does not [s2]. For older patients, hospital-at-home "probably makes little or no difference" to mortality at six months (risk ratio 0.88; 95% CI, 0.68 to 1.13) and little or no difference to the risk of being readmitted over 3 to 12 months (RR 1.14; 95% CI, 0.97 to 1.34) [s2].

What it does change: it "probably reduces the likelihood of living in residential care" at six months (RR 0.53; 95% CI, 0.41 to 0.69), may improve satisfaction with care, and "probably reduces costs to the health service" [s2]. In other words, the durable, well-supported claims are about cost, patient experience, and staying independent — not about surviving longer or avoiding the hospital next time. The single-trial readmission drop should be read against the pooled null: it is encouraging, not settled.

The residential-care finding deserves emphasis because it is easy to miss and may matter most. Being admitted to hospital is itself a risk for older people — of delirium, deconditioning and the loss of independence that can end in a care home. By treating the illness without the ward, hospital-at-home appears to protect against that cascade: the review found the intervention roughly halved the odds of ending up in residential care at six months [s2]. That is a different kind of benefit from a survival curve, and arguably a more meaningful one to the patients concerned. The Levine trial's observation that home patients spent far less of the day lying down points at the same mechanism — staying mobile at home rather than immobile in a bed [s1].

Why the results diverge

The gap between the striking US trial and the more sober Cochrane numbers is not a contradiction; it is what evidence looks like as it accumulates. Single-site trials are run by committed teams selecting suitable patients, and they tend to show larger effects than the pooled average once many settings are combined. Hospital-at-home also is not one intervention: programmes differ in which conditions they accept, how much remote monitoring they use, and how quickly they can escalate a deteriorating patient back to a ward [s2]. Safety depends on that escalation route working, which is why every trial retains "the option of transfer to hospital" [s2].

The model sits alongside a wider shift of acute and chronic care out of the clinic — from rural home-based hypertension programmes to the telehealth visit rules Medicare keeps extending. What separates hospital-at-home from lighter-touch telehealth is that it substitutes for an inpatient admission, so the safety bar it has to clear is correspondingly higher.

What this means for a reader

Hospital-at-home is one of the better-evidenced care-delivery innovations, but the honest headline is "as safe, cheaper, and often preferred," not "better outcomes." For a suitable patient — stable enough for the home setting, with a clear route back to a ward if things turn — the trials support it as a genuine alternative to a hospital bed [s1][s2]. The programmes to be wary of are those that stretch the model to sicker patients than the trials tested, or that skimp on the monitoring and rapid-transfer arrangements that make the equivalence in survival hold in the first place.

Sources

• [s1] Annals of Internal Medicine — Hospital-Level Care at Home for Acutely Ill Adults: A Randomized Controlled Trial (2019-12-16)
• [s2] Cochrane Database of Systematic Reviews — Admission avoidance hospital at home (2024-03-05)